down arrow

GlycoMimetics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US38000Q1022
USD
12.99
-0.1 (-0.76%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

12.3716.26

52 Week

0.1520.99
Valuation
Technical
Day's Volume

CASH

470.62 k

Shareholding (Mar 2025)

FII

17.99%

Held by 24 FIIs

DII

49.31%

Held by 11 DIIs

Promoter

26.95%

How big is GlycoMimetics, Inc.?

22-Jun-2025

As of Jun 18, GlycoMimetics, Inc. has a market capitalization of 8.56 million, with net sales of 0.00 million and a net profit of -29.48 million over the latest four quarters. The company reported shareholder's funds of 5.31 million and total assets of 11.09 million as of Dec 24.

Market Cap: As of Jun 18, GlycoMimetics, Inc. has a market capitalization of 8.56 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, GlycoMimetics, Inc. reported net sales of 0.00 million and a net profit of -29.48 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 5.31 million and total assets of 11.09 million.

Read More

What does GlycoMimetics, Inc. do?

22-Jun-2025

GlycoMimetics, Inc. is a clinical-stage biotechnology company focused on developing glycomimetic drugs, with a market cap of $8.56 million and a recent net profit loss of $2 million. The company has no dividend yield and significant negative return on equity.

Overview:<BR>GlycoMimetics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of glycomimetic drugs within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>- Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025)<BR>- Market-cap: USD 8.56 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -1.66<BR>- Return on Equity: -650.50%<BR>- Price to Book: 2.54<BR><BR>Contact Details:<BR>- Address: 9708 Medical Center Dr, ROCKVILLE MD: 20850-3343<BR>- Tel: 1 240 2431201<BR>- Fax: 1 240 2431018

Read More

Who are in the management team of GlycoMimetics, Inc.?

22-Jun-2025

As of March 2022, the management team of GlycoMimetics, Inc. includes Independent Chairman Mr. Timothy Pearson, President and CEO Ms. Rachel King, and six Independent Directors: Ms. Patricia Andrews, Dr. Mark Goldberg, Mr. Scott Jackson, Mr. Daniel Junius, and Dr. Scott Koenig. This team is responsible for guiding the company's strategic direction and operations.

As of March 2022, the management team of GlycoMimetics, Inc. includes the following individuals:<BR><BR>- Mr. Timothy Pearson, who serves as the Independent Chairman of the Board.<BR>- Ms. Rachel King, who is the President, Chief Executive Officer, Co-Founder, and Director.<BR>- Ms. Patricia Andrews, who is an Independent Director.<BR>- Dr. Mark Goldberg, who is an Independent Director.<BR>- Mr. Scott Jackson, who is an Independent Director.<BR>- Mr. Daniel Junius, who is an Independent Director.<BR>- Dr. Scott Koenig, who is an Independent Director. <BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Read More

Is GlycoMimetics, Inc. overvalued or undervalued?

20-Sep-2025

As of April 28, 2022, GlycoMimetics, Inc. is considered overvalued with a valuation grade of "does not qualify," reflected by a high Price to Book Value of 3.71, a negative EV to EBIT and EV to EBITDA, and an alarming ROE of -650.50%, despite a remarkable year-to-date stock return of 5096.79%.

As of 28 April 2022, the valuation grade for GlycoMimetics, Inc. moved from risky to does not qualify, indicating a significant decline in its investment attractiveness. The company is currently overvalued, as evidenced by its Price to Book Value of 3.71 and a negative EV to EBIT and EV to EBITDA of -0.29, which suggest that the market is pricing the stock at a premium despite its lack of profitability. Additionally, the Return on Equity (ROE) is alarmingly low at -650.50%, further underscoring the company's financial struggles.<BR><BR>In comparison to its peers, GlycoMimetics shows a P/E ratio of -5.9739, while DiaMedica Therapeutics, Inc. has a P/E of -12.5116, and Abeona Therapeutics, Inc. has a P/E of 5.4453, highlighting the relative valuation challenges faced by GlycoMimetics. The stock has performed exceptionally well year-to-date with a return of 5096.79%, significantly outpacing the S&P 500's 12.22% return, but this performance may not be sustainable given the underlying financial metrics.

Read More

Is GlycoMimetics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, GlycoMimetics, Inc. shows a mildly bullish technical trend, supported by bullish monthly MACD and KST indicators, despite bearish signals from the RSI and OBV, while year-to-date performance significantly outpaces the S&P 500, though it has underperformed in the past month.

As of 2 September 2025, the technical trend for GlycoMimetics, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is bullish. The RSI indicates bearish conditions on both the weekly and monthly time frames. Bollinger Bands show a bullish stance weekly and mildly bullish monthly. Daily moving averages are mildly bullish, while the KST is bullish on both weekly and monthly periods. Dow Theory suggests a mildly bearish trend weekly with no trend monthly, and OBV is mildly bearish on both time frames.<BR><BR>In terms of performance, the stock has significantly outperformed the S&P 500 year-to-date with a return of 5096.79% compared to the S&P 500's 12.22%. However, over the past month, the stock has underperformed, returning -6.16% against the S&P 500's 2.33%. Overall, the current technical stance is mildly bullish, driven by the monthly MACD and KST indicators, despite bearish signals from the RSI and OBV.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 201 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.09

stock-summary
Return on Equity

-24.16%

stock-summary
Price to Book

1.44

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-22 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-1.81%
0%
-1.81%
6 Months
6115.31%
0%
6115.31%
1 Year
4091.67%
0%
4091.67%
2 Years
655.23%
0%
655.23%
3 Years
467.25%
0%
467.25%
4 Years
749.02%
0%
749.02%
5 Years
256.87%
0%
256.87%

GlycoMimetics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is GlycoMimetics, Inc. technically bullish or bearish?

As of 2 September 2025, the technical trend for GlycoMimetics, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is bullish. The RSI indicates bearish conditions on both the weekly and monthly time frames. Bollinger Bands show a bullish stance weekly and mildly bullish monthly. Daily moving averages are mildly bullish, while the KST is bullish on both weekly and monthly periods. Dow Theory suggests a mildly bearish trend weekly with no trend monthly, and OBV is mildly bearish on both time frames. In terms of performance, the stock has significantly outperformed the S&P 500 year-to-date with a return of 5096.79% compared to the S&P 500's 12.22%. However, over the past month, the stock has underperformed, returning -6.16% against the S&P 500's 2.33%. Overall, the current technical stance is mildly bullish, driven by the monthly MACD and KST indicators,...

Read More

Is GlycoMimetics, Inc. overvalued or undervalued?

As of 28 April 2022, the valuation grade for GlycoMimetics, Inc. moved from risky to does not qualify, indicating a significant decline in its investment attractiveness. The company is currently overvalued, as evidenced by its Price to Book Value of 3.71 and a negative EV to EBIT and EV to EBITDA of -0.29, which suggest that the market is pricing the stock at a premium despite its lack of profitability. Additionally, the Return on Equity (ROE) is alarmingly low at -650.50%, further underscoring the company's financial struggles. In comparison to its peers, GlycoMimetics shows a P/E ratio of -5.9739, while DiaMedica Therapeutics, Inc. has a P/E of -12.5116, and Abeona Therapeutics, Inc. has a P/E of 5.4453, highlighting the relative valuation challenges faced by GlycoMimetics. The stock has performed exceptionally well year-to-date with a return of 5096.79%, significantly outpacing the S&P 500's 12.22% retu...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
5.91%
EBIT to Interest (avg)
-45.69
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.66
Sales to Capital Employed (avg)
0.00
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
83.85%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.71
EV to EBIT
-0.29
EV to EBITDA
-0.29
EV to Capital Employed
-3.08
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-650.50%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 8 Schemes (5.75%)

Foreign Institutions

Held by 24 Foreign Institutions (17.99%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -847.83% vs 68.06% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-21.00",
          "val2": "-2.40",
          "chgp": "-775.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-21.80",
          "val2": "-2.30",
          "chgp": "-847.83%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -2.71% vs 20.99% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-32.50",
          "val2": "-39.10",
          "chgp": "16.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-7.50",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-37.90",
          "val2": "-36.90",
          "chgp": "-2.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-3,927,529.30%",
          "chgp": "3,92,752.93%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-21.00
-2.40
-775.00%
Interest
1.10
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-21.80
-2.30
-847.83%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -847.83% vs 68.06% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-32.50
-39.10
16.88%
Interest
0.00
0.00
Exceptional Items
-7.50
0.00
Consolidate Net Profit
-37.90
-36.90
-2.71%
Operating Profit Margin (Excl OI)
0.00%
-3,927,529.30%
3,92,752.93%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -2.71% vs 20.99% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About GlycoMimetics, Inc. stock-summary
stock-summary
GlycoMimetics, Inc.
Pharmaceuticals & Biotechnology
GlycoMimetics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. Its drug candidates include Uproleselan, GMI-1687, GMI-1359, Galectin Antagonists and Rivipansel. Uproleselan is a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia and a hematologic cancer. As a life-cycle extension to uproleselan, it has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. GMI-1359 is designed to inhibit both E-selectin and CXCR4. The Galectin-3 is a carbohydrate-binding protein. Rivipansel is a glycomimetic drug that acts as a pan-selectin antagonist that binds to all three members of the selectin family, E-, P- and L-selectin, for the treatment of vaso-occlusive crisis.
Company Coordinates stock-summary
Company Details
9708 Medical Center Dr , ROCKVILLE MD : 20850-3343
stock-summary
Tel: 1 240 2431201
stock-summary
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."